Radiotherapy of Head and Neck Cancer With SIB

Local control rate.

Key aspects of local tumor control include: No Evidence of Tumor Growth: The absence of measurable or observable increase in the size of the tumor at the primary site. Tumor Response to Treatment: Complete Response (CR): Disappearance of all signs of cancer at the primary site. Partial Response (PR): Reduction in tumor size without complete disappearance. Persistence of Stable Disease: The tumor remains unchanged in size and does not spread locally beyond the treated area. Time Frame: 5 years from treatment start. Assessment Methods: Clinical Examination: Evaluation of the treated site for physical signs of recurrence. Imaging Techniques: CT, MRI, or PET scans to detect residual or recurrent disease. Biopsy: When clinically indicated, to confirm recurrence if suspected.

Regional tumor control rate

Key aspects of regional tumor control include: Absence of Disease Progression: No enlargement, growth, or new involvement of lymph nodes in the regional drainage area. Response to Treatment: Complete Response (CR): All detectable cancer in the regional lymph nodes has disappeared. Partial Response (PR): A significant reduction in the size of affected lymph nodes or nodal masses. Stable Disease: The size and characteristics of the regional lymph nodes remain unchanged after treatment, without evidence of further spread. Time Frame: 5 years Assessment Methods: Imaging: CT, MRI, or PET scans are used to assess lymph node involvement and detect residual or recurrent disease. Physical Examination: Palpation or clinical inspection for lymph node abnormalities. Biopsy or Fine Needle Aspiration: To confirm suspected recurrence or residual

Overall Survival (OS)

Overall Survival (OS) is a clinical endpoint that refers to the length of time from the start of treatment (or diagnosis, depending on the study design) until death from any cause. Key Aspects of Overall Survival: Inclusion of All Causes of Death: OS accounts for death from cancer, treatment-related complications, or any other unrelated causes (e.g., accidents or comorbid conditions). Measurement: OS as a median survival time (e.g., the time by which 50% of patients are still alive) and as a survival rate at specific time intervals (e.g., 1-year, 3 Year, 5-year OS rates). Time Frame: The starting point for measuring OS is the date of treatment initiation, The endpoint is the date of death or the last follow-up for patients who are still alive (censored data). Assessment Methods: OS is determined using survival analysis techniques, (Kaplan-Meier estimates), to calculate survival probabilities and generate survival curves.

Disease-Specific Survival (DSS)

Disease-Specific Survival (DSS) refers to the length of time from the start of treatment (or diagnosis, depending on the study design) until death specifically caused by the disease being studied, excluding deaths from other causes. Key Aspects of Disease-Specific Survival: Focus on Disease-Related Deaths: Only deaths directly attributable to the disease (e.g., cancer progression, metastasis) are considered in DSS calculations. Deaths from unrelated causes, such as accidents, other illnesses, or age-related factors, are excluded. Measurement: DSS is expressed as the time from treatment initiation to disease-specific death, or as a survival rate at specific intervals (e.g., 1,3,5-year DSS rate). Time Frame: The starting point for DSS measurement is the date of the start of treatment. The endpoint is the date of disease-specific death or last follow-up (for censored cases). Assessment Methods: DSS is determined using survival analysis techniques (Kaplan-Meier curves).

Metastasis-Free Survival (MFS)

MFS refers to the length of time from the start of treatment (or diagnosis, depending on the study design) until the first occurrence of distant metastasis (cancer spreading to distant organs or tissues) or death from any cause, whichever comes first. It is a commonly used endpoint in oncology studies to evaluate the effectiveness of treatments in preventing the spread of cancer. Inclusion Criteria: Patients are considered metastasis-free as long as there is no evidence of cancer spreading beyond the primary site and regional lymph nodes. Events Considered: Development of distant metastases (e.g. cancer in the lungs, liver, bones, or other remote organs). Death from any cause will be included in MFS, making it a composite endpoint. Measurement: MFS is expressed as the time from diagnosis or treatment initiation to the occurrence of distant metastasis or death. For patients who remain alive and free of metastases at the end of follow up the data are censored at the last FU.

Secondary malignancies

Incidence of secondary malignancies